Gastrointestinal Cancer

PD-L1 Test Debated in Gastroesophageal Cancer Immunotherapy https://t.co/qR8LAZSKNX via @medscape (@Spanishcountry)

Would be great if 🩸 for #ctDNA at the time of surgery for all MSI-H patients becomes a standard procedure, it could be compared to results a month after. Would be useful for surveillance later too #CRCSM (@manjuggm)

For early stage MSI-H rectal cancer, @AndreaCercek showed tumors melting away on IO, with pts not needing RT, chemo or surgery. Once spread via LNs, everything changes? Thought this paper from @RetickerFlynn was v interesting on LN spread https://t.co/IkcGIxMZXg (@manjuggm)

For MSI-H #CRC patients to be able to avoid surgery would be super awesome!! 85% of all CRC patients who are MSS would really really ♥️ to have more surgeries, if it would save/extend their lives, so no way surgeons will go out of business.. #CRCSM (@manjuggm)

👆👆👆"KASI Formula " especially useful in resource-limited settings @OncoAlert #CRCSM All you need is a blood test for CA19-9 & CEA (@manjuggm)

Let me shamelessly self promote the “KASI”formula🔢 that I’ve found helpful in identifying the subsets of #colorectalcancer #CRCSM early: 🧬BRAFV600E MSS 🆚 MSI-High 🆚 Others. Simple, rapid, & cheap👇🏾 ✅ CA19-9➗CEA ratio 💡Small but novel finding. https://t.co/4fccZ3RAfN (@pashtoonkasi)

Oh! and it supports MeSH terms too - this is pancreatic neoplasms (given your KRAS search): https://t.co/Iva7HxSZot (@GreeneScientist)

New pub: the use of artificial intelligence to predict the KRAS status of rectal cancer by screening of pathologic slides @acsJACS @WaleedMGhareeb1 #ColorectalSurgery @SWexner @marianaberho @juliomayol @ManishChandSurg @ConorDelaneyMD https://t.co/IalqzVU9sc (@dr_samehhany81)

Another reason to move away from Pdx1-Cre as the driver for KRAS-induced #PancreaticCancer models (in addition to head & neck squamous papillomas these mice develop). Preprint showing T-cell leukemias arising in a subset of “KC” mice. https://t.co/MIiERVyrMG (@Aiims1742)

In @JNCI_Now: The molecular landscape of #PancreaticCancer & #BileDuctCancer for novel targeted therapies from real-world genomic profiling (via @FoundationATCG) https://t.co/d20dqJimEw Key take home: make sure that at least #KRAS wild type & young onset cancers are sequenced! (@Aiims1742)

Grateful to be selected for the 2022 @AACR @ASCO Methods in Clinical Cancer Research Workshop in July! Looking forward to learning how to design effective clinical trials for patients with KRAS and BRAF mutated #CRC! @skopetz @VanMorrisMD @ParseghianC #crcsm (@MadhuEluri)

We are proud of you @MadhuEluri to see the great work you will do and the skills you will learn through the @ASCO @AACR Vail workshop to help BRAF mut #crcsm pts! A true🌟 from @UNC @IMResidencyDuke and now @MDAndersonNews ! #endcancer (@VanMorrisMD)

@DrHendifar @PancPathologist have had success w/ #ALK fusion in metastatic #PDAC following #FOLFIRINOX responsive to #alectinib then acquired alectinib-resistant ALK mutations G1202R and V1180L on G360, then w/benefit to 3rd-gen ALK inh #lorlatinib https://t.co/JnI2dntOfv #pancsm (@jgong15)

Pembro + CROSS in GEJ from Dr. Harry Yoon, @GIcancerDoc, @the_danielahn and team in @CCR_AACR. Exploratory PD-L1 expression on extracellular vesicles is interesting. https://t.co/kEnFeuVqZg (@KlempnerSam)

Also, a related observation. #FUSIONS 🧬🧬in #CRCSM #ColorectalCancer can be acquired post EGFR⛔️. You said your patient progressed on 2nd line therapy. Did the patient get anti-aEGFR? Regardless, something that can be picked up on #ctDNA. @JCOPO_ASCO https://t.co/5X27m4qZYX (@pashtoonkasi)

Excellent job @LaurenGambleMD discussing Diffuse-type gastric carcinogenesis in germline CDH1 variants for your Senior Tea Talk! @JeremyLDavisMD @NCICCR_SurgOnc #gastriccancer #CDH1 #SurgOnc (@NCI_SurgOncFel)

Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response https://t.co/epEkqkdWoU (@VivekSubbiah)

.@NataliyaUboha of @UWHealth is leading #clinicaltrial EA2183, researching the addition of radiotherapy to chemotherapy for patients with oligometastatic HER2(-) EGA. For more: https://t.co/YDD5pHTSZX #esocsm #StomachCancer cc: @StomachCancer_ @NoStomach4Cancr @GastricCancerFD (@eaonc)

The only parallel experience I have is a complete block of approval for alectinib despite appeals for an ALK fusion positive cholangiocarcinoma patient of mine. I'm trying to get it from the company 🙏 (@MPishvaian)

Shout out to my fellow #GIonc crew. Have a young Burmese patient with EMLA-ALK fusion mutation via NGS in metastatic #crcsm, progressing on 2nd line FOLFOXIRI. Very scant data in alectinib in this setting. Anyone with clinical experience? @pashtoonkasi @marklewismd @doctorC369 (@realbowtiedoc)

#ASCO22 ➡️abstracts drop on May 26th 📢#GICancer peeps - here are the presentations I will be watching out for!👇 🌟🌟Plenary- PARADIGM T.Yoshino #CRCSM 🌟Special Sessions -neoadjuvant #rectal PD1 @AndreaCercek -DYNAMIC #ctDNA @JeanneTiE🧬 #HPBCSM #PANCSM #STCSM #ESOCSM #ANCSM (@GillSharlene)

We evaluated Fibroblast Growth Factor Receptor inhibitors in our xenograft models of gastrointestinal stromal tumor. Some efficacy, unlikely a game changer, and again no added value when combining with imatinib. See Schöffski et al., doi: 10.3390/biomedicines10051135 (@schoffski)

Really needed and very much looked for info on Progression-Free Survival in Patients With Cholangiocarcinoma With or Without <i>FGF/FGFR</i> Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response https://t.co/JU4MEAnQXj . Great team work @MSKCancerCenter! (@GABOUALFA)

Brilliant presentation by @UABSurgery resident and @BeierleLab member Dr. @RMarayati at #APSA22 on her work exploring PIM kinase’s role in promoting hepatoblastoma mets via CXCR4. Thanks for letting us borrow her from your service Dr. @herbchen! @APSASurgeons (@BownesLaura)

🆕@JCOPO_ASCO @ASCO ✅NGS🧬upfront for #colorectalcancer #CRCSM. We always talk about POSITIVE selection🔐. NEGATIVE ultra- hyper-selection to see who should get EGFR⛔️is equally important. Beyond RAS/RAF/sidedness; HER2 etc. @OncoAlert OS📈5️⃣1️⃣months. https://t.co/9kMcoU4H3l (@pashtoonkasi)

Glad to be part of this meeting faculty with a talk about #FGFR gene fusion as a #target for novel #treatments especially for #cholangiocarcinoma #CCA @NicolaNormanno @AIOMtweet @HUNIMED @HumanitasMilano (@LorenzaRimassa)

⭐️Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Gastric cancer 🧬🎯 Overall response rate (ORR) = 48.6 % Disease control rate (DCR) = 73.0% @NatureMedicine #precisionmedicine (@VivekSubbiah)

#TumorBoardTuesday 🤔With that family👨‍👨‍👧‍👦history, it would seem critical to assess for an underlying germline🧬mutation ☝️I can connect the dots on breast, prostate, & even uterine cancer (BRCA1/2), but not sure if the colon cancer fits in❓ @HHampel1 @CCAlliance @BRCASTRONG (@MPishvaian)

@OncoAlert Claudin18.2-specific CAR-T cells in GI cancer? ORR=48% @NatureMedicine @gary_lyman @mshadman (@NicoleKuderer)

3. CMS1 microsatellite instability (MSI-H) and microsatellite stable (MSS) colorectal cancers exhibit similar activation of tumor epithelial cells. Infiltration of CD8+ cytotoxic T cells may explain why MSI-H CRCs are responsive to immune checkpoint inhibitors (@ashiq_masood)

Monitoring AEs of Trastuzumab Deruxtecan in HER2+ Gastric Cancer https://t.co/GU2iPegSuk via @targetedonc @marshalj23 @LombardiCancer @MedStarGUH (@RueschCenter)

In @jclinicalinvest A p300/GATA6 axis determines differentiation and Wnt dependency in #PancreaticCancer models https://t.co/7ISifBQcKO What renders certain RNF43 mutant cancers resistant to Wnt ligand inhibitors? This study suggests loss of EP300/GATA6 induced differentiation. (@Aiims1742)

Have cellular therapies finally made an impact on solid tumors? Claudin18.2-specific CAR T cells in gastrointestinal cancers. Published in @Nature. The ORR was 48.6%. (mostly gastric and pancreatic cancer). 👇🏽 👇🏽 https://t.co/1hms1jlUtp (@ShaalanBeg)

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review https://t.co/NawIpKpYso (@VivekSubbiah)

A study led by @PeterHoseinMD of @SylvesterCancer found a subgroup of pancreatic cancer patients with BRCA and RAD51C mutations were more likely to respond to immunotherapy. #pancsm https://t.co/5Hx7tGnpLa (@CancerResearch)

EA2183 is a phase III study of consolidative #radiotherapy in patients with #oligometastatic HER2 negative #esophageal and gastric #adenocarcinoma. Learn more: https://t.co/YDD5pHTSZX cc: @NataliyaUboha, @luckydoc2, @mgibson21212 #StomachCancer #GICSM #esocsm (@eaonc)

@nlindenberg I don’t know if I agree since a more comprehensive look 👀 at all possible aberrations wasn’t till 3rd line. Advances are coming in “SUBSETS of SUBSETS” @aparna1024. In #CRCSM cannot afford to not identify ✅EARLY your ✔️MSI⬆️ ✔️POL-🧬 ✔️HER2 ✔️NTRK ✔️G12C ✔️V600E (@pashtoonkasi)

Out latest "Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer" showing (among other things) that CAV1 serves as a predictive for HER2 therapies. Lead by the amazing @Pat_MRP_PhD https://t.co/YXqrLVMLJY with @km_tully @YJanjigianMD (@LewisLabMSKCC)

👆🏾Shows how inadequate “à la carte” based testing is for not just #colorectalcancer but all GI malignancies 🆚 PANEL-based. Not just MMR/MSI, but EXTENDED RAS/RAF, HER2, TMB, BRCA/DNA-Repair, etc. 💡Similar to lung, PANEL based more💲 effective & will preserve more tissue. (@pashtoonkasi)

Agree @DrBonillaOnc. And for those who might have missed this, here’s data on “CTLA4⛔️ rescue” post-PD1⛔️blockade in dMMR/MSI⬆️ #colorectalcancer. 👇🏾Presented at @sitcancer earlier, now published @jitcancer. #JITC. Data is there for other tumor types e.g. melanoma etc, now GI. https://t.co/WpwJUiyaqO (@pashtoonkasi)

I’d argue that immunotherapy should have been second line. This is probably the only MSS #colorectalcancer situation where the TMB cutoff of 10 for IO approval of pembrolizumab makes sense. 👇🏾My pt➡️ PD1⛔️. The #BRCA in a ULTRA-HYPER-mutated I’d not go after first. ?passenger. https://t.co/gNRVDUTkoX (@pashtoonkasi)

I think the point @TristanRutland7 is making is that colon cancer can be TTF pos (well known fact). The clone was 8G7G3/1 here but SPT24 is even more promiscuous. The case he presented is also pos for CDX2 and SATB2 + looks like colon cancer + there is a history of colon cancer. (@smlungpathguy)

Great thread. @JackWestMD check out this TTF-1 positivity in colonic cancer. (@smlungpathguy)

Some data gaps make it hard to follow clinically, eg what stage was the colon cancer 5 years prior and if adjuvant treatment was given; extension of current disease beyond that lung lesion, and we would at least have the NGS of current cancer. KRAS G12C will give a good hint L>C (@DrBonillaOnc)

Given the lack of absolutes in medicine, lest in cancer, you already know the answer 😉 that’s why we say matching mutations. The clonal evolution of colon cancer is quite rare in absence of treatment hence using block you had for TTF-1 also good for NGS or small panel. (@DrBonillaOnc)

I don't think colon cancers are ever TTF1 +, so I agree. (@davideyoungmd)

This preprint examines changes in neutrophil:lymphocyte ratios (NLR) during neoadjuvant Rx & observes an independent prognostic benefit. Preclinical studies demonstrate the importance of disrupting the neutrophil-CAF-#PancreaticCancer IL-1B/IL-6/STAT3 axis during neoadjuvant Rx. (@Aiims1742)

Next preprint from @PacmenC team at @UMRogelCancer & @HenryFordHealth (@Pasca_Lab @HCCvPDAC et al): Hypoxia promotes an inflammatory phenotype of fibroblasts in #PancreaticCancer https://t.co/D25yx4z4yx In brief, hypoxia upregulates IL1a expression driving an iCAF phenotype. (@Aiims1742)

This preprint examines both cell autonomous changes & alterations to the tumor immune microenvironment in #PancreaticCancer with KRAS p53 co-mutations (present in majority of cases), and identify a “immunoregulatory program” (IRP) associated with chemoresistance & worse survival. (@Aiims1742)

First up, a double header from @DrJashDatta & @NbmerchantMD @SylvesterCancer. Preprint 1: Distinct Mechanisms of Innate & Adaptive Immune Regulation Underlie Poor Oncologic Outcomes Associated with KRAS-TP53 Co-Alteration in #PancreaticCancer. https://t.co/d5zthHVQMq (@Aiims1742)

Preprint 2 from @DrJashDatta & @NbmerchantMD: Neutrophil-Mediated Stromal-Tumor IL-6/STAT-3 Signaling Underlies the Association between Neutrophil-to-Lymphocyte Ratio Dynamics and Chemotherapy Response in Localized #PancreaticCancer https://t.co/ExKeM7zIBK (@Aiims1742)

Next preprint from @JanelKopp @JimJohnsonSci @annizubc: Insulin receptors in pancreatic acinar cells contribute to KrasG12D-driven #PancreaticCancer initiation in the context of diet-induced obesity. Very interesting sex-specific differences. https://t.co/KzPvpYqrIV (@Aiims1742)

Previously, this team had demonstrated the impact of endogenous hyperinsulinemia on #PancreaticCancer progression. https://t.co/ddq3wLrF7L This preprint drills down on the target cells driving that effect, using an acinar cell specific insulin receptor knockout. (@Aiims1742)

Original Article 👉RIP140 regulates POLK gene expression and the response to alkylating drugs in colon cancer cells🌺 https://t.co/y2XCtMRqG6 @sjnurkin @skopetz @AasmaShaukatMD @AJacomeMD @elena_elez (@cdrjournal)

Special @AACR conference on #Livercancer underway now! @mpiquegili gives short talk on TGF-beta in #HCC #LiverTwitter @IcahnMountSinai #llovetlab (@MountSinaiLiver)

USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer | Nature Communications https://t.co/ykoX3PU1sK (@weldeiry)

Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of #colorectalcancer patients https://t.co/h7nli0iqTz (@AlfredoBudillon)

Today in @Cancer_Cell from @brekkenlab @utswcancer identifying a putative source for the variant of cancer associated fibroblasts (CAFs) known as antigen-presenting CAFs in #PancreaticCancer -mesothelial cells. Mesothelial cells 👉🏽 apCAF 👉🏽 CD4+ Tregs https://t.co/KGHz760rPY (@Aiims1742)

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability https://t.co/mnt3JxDJp0 (@oncoOuLungCA)

Curiouser and curiouser. I just learned the word "BRCAness" today from my virtual molecular tumor board results (via TRACK study) for #cholangiocarcinoma in re my #ARID1A mutation. Recommended pembrolizumab & olaparib upon recurrence. Just for interest... (@intraccsurvivor)

Case of success! complete response in a patient with pembrolizumab and olaparib-treated advanced #pancreaticcancer with the germline #BRCA1 mutation and high tumor mutation burden after first-line platinum-based chemotherapy. https://t.co/Q80Xu2bKvN (@Dr_Ivanoncologo)

Given the prevalence of G12D in >50% of all PANC patients and >13% of all GI cancers. Having a small molecule inhibitor will bring meaningful impact to the lives of cancer pts. @incVrise, we intend to bring this opportunity to clinic soon. @PanCAN @CCAlliance @KRASkickers (@IncVrise)

Yes! My colleagues @TimGreten and @MitchellHo have a clinical trial evaluating GPC3-specific CAR T cells in patients with #HCC #livercancer https://t.co/iz5ocU12UC (@freddyeescorcia)

Preprint: ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and #PancreaticCancer progression https://t.co/Z9Sfo2h139 A related paper showing impact of ST6GAL1 knockout in autochthonous PDAC: https://t.co/2df7kx1WBM So many glycans altered in pancreatic neoplasia! (@Aiims1742)

MUST SEE TV @rachnatshroff on precision oncology in #cholangiocarcinoma. *Importance of biomarker testing *#FGFR inhibitor infigratinib in #FGFR2-fusion-positive CC. Presented by @melinda_bachini for @curecc #cholangiotwitter #livertwitter #onctwitter https://t.co/r6OGBu5riE (@intraccsurvivor)

Now out by @margheambro1 ALK inh in Patients With ALK Fusion–Positive GI Cancers: An International Data Set and a Molecular Case Series. Thanks to all coauthors ! @Marzia_DelRe @KlempnerSam @JamesClearyMD @paomanca @alexdrilon Is ALK an agnostic target? https://t.co/IbHjFOYkg1 (@FilippoPietran4)

Association of microsatellite instability (MSI) status with the 5-year outcome and genetic ancestry in a large Brazilian cohort of colorectal cancer - Great contribution from Brazil! https://t.co/7EOUcmoa91 (@AndresFCardonaZ)

MCW Discovers. Mutational Landscape of KDM6A. KDM6A mutations can cause pancreatic cancer in females ⁦@lustgartenfdn⁩ ⁦@PanCAN⁩ ⁩ ⁦⁦@MCWSurgResearch⁩ ⁦@Dr_R_Kurzrock⁩ ⁦@MCWCancerCenter⁩ ⁦@MCWPancProgram⁩ ⁦@arlenewilsonlee⁩ (@precision_ru)

MCL1 in the Nucleus Appears to Drive Chemoresistance in Colorectal Cancer https://t.co/8ltzWxuC91 via @CleClinicMD @BrianGastmanMD @ClevelandClinic (@jamecancerdoc)

Dr. Tanios Bekaii-Saab (@GIcancerDoc) reports promising results of the KRYSTAL-1 trial, which targets a KRAS mutation common to pancreatic cancer. https://t.co/wwnA56mNls (@letswinpc)

Here it is👇 “Low MUTYH expression was observed significantly more often in undifferentiated-type gastric cancer” https://t.co/t0CXS9Ip5A (@FogacciJoao)

#guardanthealthamea #guardanthealth #webinar #guardant360 #guardantreveal #liquidbiopsy #lungcancer #colorectalcancer (@GuardantAMEA)

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer | The Oncologist | Oxford Academic https://t.co/zLCVium7Ip (@mgfakih)

I really agree w/you: CPS<5👉+ IO just for ⬆️ORR! Although, we recently discussed a rare case of gastric cancer with CNS metastasis + PDL-1 negative (& good PS)😊Despite the neg PDL-1, we suggest chemo+IO based on this interesting Korean case report: https://t.co/CoBmKJW5jd (@KellyBorgesAra2)

Dr. Tanios Bekaii-Saab (@GIcancerDoc) reports promising results of the KRYSTAL-1 trial, which targets a KRAS mutation common to pancreatic cancer to our partner @letswinpc. https://t.co/GLtxMTYKTo (@EHS_PCAF)

#TumorBoardTuesday 9/13 👨‍🎓... 📌MAP: ⬇️ polyps than FAP 📌MAP-CRC ≈ dMMR/MSI-H CRC ✅Proximal ✅Mucinous ⬆️Prognosis @RenataDAlpino @jaypsv @Alinechaves73 @AJacomeMD @GIcancerDoc @Juanma19712012 @RachelRiechelm2 @manjuggm @pashtoonkasi https://t.co/08fI6HY0s7 (@FogacciJoao)

@GIcancerDoc presented amazing data about KRASG12C inh #GI22 (@FogacciJoao)

#PreTest Q 2️⃣ #CME #TumorBoardTuesday Free CME 🔗: https://t.co/63osUKLysL 🧐 What’s *special* about MUTYH mt biallelic tumors? 🧬 @MPishvaian @FogacciJoao @JohnEbbenMDPhD #GEA #ColorectalCancer (@TumorBoardTues)

Yes! Ppl got extra time from Dr. Corcoran's Spartalizumab+BRAFi+MEKi trial & the @VanMorrisMD Beacon+IO trial We need a few efficacious lines of tx for BRAF mCRC. Even with these trials, people seem to get at best 15-18 months after dx Very few long term survivors, sadly #CRCSM (@manjuggm)

I am really interested to see if chemo+targeted therapy is really better than sequential treatment with chemo & targeted therapy with respect to durability of response & appearance of resistance clones BRAF mCRC subgroup of #CRC needs many more tx strategies for sure #CRCSM (@manjuggm)

Young patient with PIK3CA E542K mut/RAS WT metastatic colon cancer. Currently has good response with iri/panitumumab after FOLFOX. If he progresses, any reason to believe everolimus or alpelisib will work? Should I add low-dose aspirin? @pashtoonkasi @Dr_R_Kurzrock @GIcancerDoc (@fernandbteich)

.@NataliyaUboha of @UWHealth is leading #clinicaltrial EA2183, researching the addition of radiotherapy to chemotherapy for patients with oligometastatic HER2(-) EGA. For more: https://t.co/YDD5pHTSZX #StomachCancer #GICSM cc: @StomachCancer_ @NoStomach4Cancr @GastricCancerFD (@eaonc)

IKF is happy to announce that the ADVACE study has recruited its first patient. The IIT led by Prof. Arndt Vogel evaluates an innovative combination of Atezolizumab and Derazantinib for pts with bile duct cancer and FGFR fusions/rearmaments (@salahAlBatran)

@KRASKickers has a pan-KRAS group for patients. Hoping that KRAS mutation offers opportunity for intervention in pancreatic cancer. @TerriConneran (@fireflyann)

Nice study from Moshe Oren @WeizmannScience in @PNASNews Cross-talk between mutant p53 & p62/SQSTM1 augments #PancreaticCancer cell migration by promoting the degradation of cell adhesion proteins https://t.co/yYZUCw2L3w Highlighting a key difference between R273H & R175H allele (@Aiims1742)

In @jclinicalinvest Insight: Epigenetic drug screening defines a PRMT5 inhibitor sensitive #PancreaticCancer subtype This preclinical study identified a signature of MYC deregulation (amongst others) linked with sensitivity to PRMT5 inhibitors. https://t.co/Vlp79nK4nA (@Aiims1742)

Single-extracellular vesicle analysis (sEVA) of mutated proteins allows detection of stage 1 #PancreaticCancer Interesting approach to detect mutated KRAS & p53 proteins (versus DNA) in shed EVs, identified 15 of 16 patients with stage 1 PDAC. https://t.co/fT9NDLhStt (@Aiims1742)

Thank you for your kind words. Honored to be part of this important team science effort to target KRAS in #PancreaticCancer. Lots to do & learn, and our team can’t wait to get started. Thanks @break_cancer & @lustgartenfdn 🙏🏽💜 (@Aiims1742)

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study [Jul 30, 2021] @JavleMilind et al. @BurrisSkip @TheLancetOncol https://t.co/lddVSt9jFm #NCT02091141 #PrecisionMedicine #hpbcsm (@mtmdphd)

Mutations in TP53 in #inflammatoryboweldisease IBD-CRCs and #sporadic #colorectalcancer are significant @MDAndersonNews @MSKCC_BreastCA @ESMO_Open @JCO_ASCO (@sanchu153)

ccRCC. Only other approval of VEGF is in HCC but no dual ICI in liver cancer. (@BReinfeld)

Interesting study on the use of Ipi/Nivo in a few pts met. panc. or BTC (CR!) with homologous recombination deficiency. Should be studied more!!!! https://t.co/CJx5cEkhQQ via @JAMAOnc part of @JAMANetwork @curecc #immunotherapy #pancreaticcancer (@TimGreten)

what I've been experiencing with @KRASKickers is that the scientists and the expert oncologists really, really like meeting with patients. So give a presentation but then take Q&A. @GIcancerDoc @kevansf @D_B_McConnell (@fireflyann)

Dr. Tanios Bekaii-Saab (@GIcancerDoc) reports promising results of the KRYSTAL-1 trial, which targets a KRAS mutation common to pancreatic cancer. https://t.co/wwnA565bWS (@letswinpc)

Dr. Tanios Bekaii-Saab (@GIcancerDoc) reports promising results of the KRYSTAL-1 trial, which targets a KRAS mutation common to pancreatic cancer. Learn more from our partner @letswinpc. https://t.co/GLtxMTH9uO (@EHS_PCAF)

Thanks to Dr @skopetz for a great talk on "Overview of KRAS-directed therapies for #colorectalcancer" The video is now available in the COLONTOWN University Lecture Hall https://t.co/PvxltoMCVo #CRCSM #KRAS @colontown @paltown1 (@manjuggm)

Happy to share the latest publication from our team @SylvesterCancer examining immunotherapy in patients with pancreas cancer with homologous recombination deficiency (mostly BRCA1/2 and RAD51C) out today in @JAMAOnc https://t.co/AGnaizwydQ (@PeterHoseinMD)

Cologuard testing is technically a FIT-DNA test, incorporating both a traditional FIT test for hemoglobin with molecular assays for DNA mutations associated with colon cancers. It’s considerably more sensitive, albeit less specific, than FIT testing alone. (@MBLevineMD)

Great "DocTalk" by Dr @skopetz, Professor & Deputy Chair, GI Medical Oncology from @MDAndersonNews for #CRC patients & caregivers in @colontown Always great to have Dr. Koptez with us. Video coming to COLONTOWN University Lecture Hall shortly. #KRAS #CRCSM (@manjuggm)

#GDUGI2022 The Non-operative management of rectal cancer! Great talk by Dr @JoshSmithMDPhD #CRCSM If your rectal cancer is MSI-H..what's new? Conclusions Very informative talk. (@manjuggm)

#GDUGI22 Session I: Current Developments in Colorectal Cancer. Approach to BRAF and KRAS mutated CRC talk by Dr Ryan Corcoran. As always, very informative talk. (@manjuggm)

#GIMedOnc 60 yo male diagnosed with pT2N0 resected hilar cholangiocarcinoma. IHC shows dMMR (loss of MLH1 and PMS2). ECOG 0. What would you offer for adjuvant therapy? @GrupoGTG @rachnatshroff @pashtoonkasi @JulianaRBeal @mzugman @cornellGIcancer @esinghimd @ASCO @myESMO (@PestanaRC)

🎊We share with you #Review "Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers" in #mdpiDiseases, 👥by Dr. Jun Gong et al. @jgong15 Enjoy reading 🔗https://t.co/UmNrywAHvL Keywords: #gastroesophageal #cancer #trastuzumab #HER2 (@Diseases_MDPI)

The “Conquering KRAS in #PancreaticCancer” team (a partnership between @break_cancer & @lustgartenfdn) will leverage the emerging KRAS-targeted therapies to understand mechanisms of resistance & novel combinations. @DrShubhamPant @RonDePinho @rkalluriMDPhD @EileenMOReilly (@Aiims1742)

EA2183 is a phase III study of consolidative #radiotherapy in patients with #oligometastatic HER2 negative #esophageal and gastric #adenocarcinoma. Learn more: https://t.co/YDD5pHTSZX cc: @NataliyaUboha, @luckydoc2, @mgibson21212 #StomachCancer #GICSM #esocsm (@eaonc)

Great thread by @DrGarciaAguilar that summarizes the main findings from our most recent manuscript investigating the role of #KRAS mutations in #colorectalcancer. Don't hesitate to check it out! (@fsanchezvega)

KRAS mutant colorectal cancer upregulates integrin α6β4 through ERK/MEK signaling. (2/8) (@DrGarciaAguilar)

Our latest manuscript is out in @MCR_AACR. We show that ITGB4 is over-expressed in KRAS-mutant #colorectalcancer and knocking it down diminishes local invasiveness and rates of lung #metastasis. (1/8) https://t.co/kXsXRIJ7lu (@DrGarciaAguilar)

Coming up: Don’t miss our next #colorectalcancer Doc Talk! Tuesday 4/19 at 2 pm EDT, join Dr. Kopetz (@skopetz) from MD Anderson Cancer Center for a discussion on KRAS-directed therapies for colorectal cancer. Register for free: https://t.co/El9Tq4v5QJ (@paltown1)

High rate of complete response @MDAndersonNews following neoadjuvant immunotherapy for locally advanced #dMMR #MSI-H #CRC. Potential for a new paradigm for CRC treatment without surgery? #yocrc #OncSurgery #crcsm https://t.co/SrWzlU4haK (@ColonCancerDoc)

Dr. Tanios Bekaii-Saab (@GIcancerDoc) reports on the promising results of the KRYSTAL-1 trial, which targets a KRAS mutation common to pancreatic cancer. https://t.co/wwnA56mNls (@letswinpc)

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study - The Lancet Oncology https://t.co/wAyUiSHoD7 (@VivekSubbiah)

Recent single institution study by @GIcancerDoc @MayoClinic had suggested increased prevalence of BRCA1/2 mutations in gastroesophageal cancers. Now cholangiocarcinoma should be added to list of universal germline testing. @JavleMilind @rachnatshroff @pashtoonkasi @MPishvaian (@Aiims1742)

In @JAMAOnc Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants https://t.co/GWx5o0rqxu Large case control registry study finds three additional solid cancers with increased risk in BRCA1/2 carriers - biliary tract (cholangiocarcinoma), gastric & esophageal. (@Aiims1742)

Thanks—must have missed it in the thread. Mutations are usually the first thing we talk about with advanced biliary tract cancers. Nothing potentially first line other than MSI-h/MMR-d with pembro. iCCA being amongst the most rich and targetable of them all. @MJavle (@drymtn)

I was proud to take part in this panel program alongside masters of the field, Drs. @marshalj23, @AnelisaCoutinh1 and Takayuki Yoshino. CME credits available until April 30. Get SMART: Diagnostics and Targeted Treatment for HER2+ Metastatic Gastric and Colorectal Cancers. #AACR22 (@cancerassassin1)

ICYMI: the NIH Hereditary Gastric Cancer Symposium sessions can be viewed online now. Day 1: https://t.co/RDI8xPfXxU Day 2: https://t.co/aevMY3DHTg @NCIResearchCtr @NCICCR_SurgOnc #CDH1 #HDGC (@JeremyLDavisMD)

🚨T-2 hours! @W_Park_MD takes us through a tour-de-force on FGFR alterations and 💊 in #cholangiocarcinoma 🚨 Follow @TumorBoardTues to stay up-to-date and join us at ⏰ 7PM CST to join the convo! @UWCarbone @curecc @doctorC369 @CCA_Alliance @loconte (@JohnEbbenMDPhD)

One important lesson from the #AACR22 session on #PancreaticCancer where Dr. @EileenMOReilly stressed the importance of somatic & germline sequencing, especially in young onset PC (<50Y). The PALB2 mutation has been pivotal to the welcome response & long term survival seen here. (@Aiims1742)

A standout point from a clinical trial led by @YJanjigianMD at @MSKCancerCenter is how many people with HER2-positive esophageal and gastric cancers are helped by adding pembrolizumab to standard care. https://t.co/lHZ1ugdA0z (@CancerResearch)

KRAS G12D got the most votes! Anyone surprised based on what they heard today and throughout #AACR22? Bring it on - if we can target G12D it will have even more potential impact than G12C due to higher prevalence across cancers - including many GI tumor types. @AACR (@cancerassassin1)

Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor talk by Mallika Singh- Mice studies @AACR #AACR22 #CRCSM (@manjuggm)

Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor talk by Mallika Singh @AACR #AACR22 #CRCSM (@manjuggm)

With ref to @jocelynkaiser article below, I am so excited that the first patient at high-risk for #PancreaticCancer has been enrolled in the KRAS #vaccine trial led by Drs. @NeehaZaidi & @DrLizJaffee. Thank you @SU2C & @lustgartenfdn for funding this interception trial. #AACR22 https://t.co/voyNgGvIvI (@Aiims1742)

WATCH: @skopetz, of @MDAndersonNews, discusses the phase 3 BEACON CRC study and the subsequent efficacy response analysis in patients with BRAF V600E–mutant metastatic colorectal cancer. #crcsm #oncology https://t.co/xDQvLFEqTK (@OncLive)

.@EileenMOReilly spoke at #AACR22 about the good news and bad news in #PancreasCancer: higher incidence in young people and some recent phase III studies with sobering results, but shared why she's excited about other therapies in development, including #KRAS targeted therapies. (@MSKCancerCenter)

@FightCRC @prof_gina_brown @colorectaltweet @colorectal_jay @kgnairmd @DrMikeValente @CoryChevalier @RabiHannaMD @IbrahimSahinMD1 @skopetz @pashtoonkasi @DFarberYoungCRC @prof_gina_brown @CRCequity @colorectal_bio @CYOC_MSK @ccor_study @cacoloncancer @GIcancerDoc @Cologuard (@YLeyfman)

Elegant work by @samirzaidi from @CharlesSawyers lab on mechanisms (JAK/STAT, FGFR) of multilineage plasticity towards NE and EMT states in #CRPC. Hints of similar plasticity in #PancreaticCancer. Common pathways, shared vulnerabilities? #AACR22 @davetingmgh @arnavmehta3 (@DrWilliamHwang)

#AACR22 @mserenaroca recipient #Pezcoller travelaward present Repurposing of #valproicacid and #simvastatin in #pancreaticcancer: in vitro and in vivo synergistic antitumor interaction and sensitization to gemcitabine/nab-paclitaxel via inhibition of TGFβ-EMT signaling pathway (@AlfredoBudillon)

🎯🧬Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19–FGFR4–KLB Pathway Inhibition @montypal @CD_AACR @AACR #AACR22 https://t.co/9e5HUEkts9 (@VivekSubbiah)

Both tumor and circulating mutational profiling are important! RAS+TP53 comutation is associated with #ctDNA detection after hepatectomy for #colorectalcancer liver metastases. @VautheyMD @hpb_so @vreelant @AHPBA @IHPBA @MDAndersonNews #oncsurgery #endcancer @pashtoonkasi (@timnewhook19)

Impressed how some topics come up in 3-5 Qs from ASCO SEP & I expect to be locks on ABIM test: T-DM1 for HER2+ breast cancer after neoadj, consol durva for st 3 NSCLC, MAP post-op chemo for osteosarc, cont f/u after cCRT out to 26 wks for anal cancer need to make a list to share (@JackWestMD)

⁦@mserenaroca⁩ #AACR22 11/4 #1840 Repurposing of valproic acid and simvastatin in pancreatic cancer: in vitro and in vivo synergistic antitumor interaction and sensitization to gemcitabine/nab-paclitaxel via inhibition of TGFβ-EMT signaling pathway https://t.co/eSqyxJx43Z (@AlfredoBudillon)

Acute aerobic exercise‐conditioned serum reduces colon cancer cell proliferation in vitro through interleukin‐6‐induced regulation of DNA damage - International Journal of Cancer Interesting & provocative as IL6 can promote cancer and is a therapy target https://t.co/cXrAF98clI (@weldeiry)

New insights into Kras-mediated pancreatic adenocarcinoma, including remodeling of the tumor immune microenvironment https://t.co/7aOVmvYjan @UmaMahadevanIBD @IBDMD @RickPeekMD @Aiims1742 (@DouglasCorley)

Get SMART: Diagnostics and Targeted Treatment for HER2+ Metastatic Gastric and Colorectal Cancers. Join John Marshall, MD (@marshalj23); Anelisa Coutinho, MD; Emil Lou, MD, Ph.D., FACP (@cancerassassin1); and Takayuki Yoshino, MD, Ph.D., via @myCME. https://t.co/lnbKpfqzWn (@RueschCenter)

Rounding inpatient #KRASG12C 🫁 #NTRK 🫁 #HER2➕➕➕ gallbladder cancer/cholangiocarcinoma More 🧬 tests brewing. Welcome #PrecisionMedicine #PrecisionOncology. (@pashtoonkasi)

Great session with @KRASKickers today with @kevansf Will be joining the video archive KRAS Kickers Connect: Drugging All Forms of KRAS: Where We’re At, @D_B_McConnell https://t.co/ftUsgEXshQ Kicking GI Cancer’s KRAS @GIcancerDoc https://t.co/LA100qVRiH 1/2 (@fireflyann)

15. #TOPAZ1: Ph3, 1L in advanced biliary tract cancer: Durva + Gem/Cis vs. Gem/Cis (current SoC). Improved OS (HR: 0.80) and PFS (HR0.75) with addition of Durva. Benefit seen regardless of PDL1 expression. 2yr OS: 24.9% Vs 10.4% @pashtoonkasi Modest benefit noted. (@OncBrothers)

Yes, Judy Garber is one of my mentors and I have learned much from her. You are welcome to visit us again at DFCI if there is ever a need. We are now offering pancreatic cancer screening to patients with BRCA1/2+ and a family history of pancreatic cancer. (@DrBBychkovsky)

Kicking off Day 2 of #HDGCSymposium2022 with discussion of gastric cancer risk, genetic testing, and role of RNA testing. @StanfordMed @rachidkaram @tischkowitz @gracefulDNA #CDH1 (@JeremyLDavisMD)

@JeremyLDavisMD discusses long-term sequelae of #CDH1 prophylactic total gastrectomy and ongoing questions at #HDGCSymposium2022 @NCICCR_SurgOnc @NCIResearchCtr @NoStomach4Cancr @StomachCancer_ https://t.co/PYvxGz1d2P (@sarahgsam)

𝐉𝐮𝐬𝐭 𝐏𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝: Robust Response to Futibatinib in a Patient With Metastatic #FGFR-Addicted #Cholangiocarcinoma Previously Treated Using Pemigatinib: https://t.co/caMYe4wetI By @DrCrystalD and Dr. Anil Rengan at @FoxChaseCancer (@JNCCN)

Honored to present on #CDH1 endoscopic gastric cancer surveillance at @NCICCR_SurgOnc. Thank you to my mentors @JeremyLDavisMD #TheoHeller @ChrisKohMD ! (@bilalasifMD)

Good luck. To reduce background you can try more dilute 1° ab, shorter incubations, &/or different antigen retrieval. Also, some of my cases DO show high cytoplasmic background . . . I'm looking for loss of nuclear staining. Both of these cholangiocarcinomas are "BAP1-lost." (@IHC_guy)

.@NIDDKgov Dr. Bilal Asif will be speaking about the Safety of Endoscopic #GastricCancer Surveillance in #CDH1 carriers at 1:30pm. Join us #HDGCSymposium2022. .@NoStomach4Cancr @GastricCancerFD @StoCANcer @StomachCancer_ @DeGregorioFF (@JeremyLDavisMD)

Top-Down Proteomics Reveals the KRAS Proteoform Landscape in Colorectal Cancer --via @theNCI @FredNatLab https://t.co/RhCte5thTA (@cancerassassin1)

How reliable is signatera testing for pancreatic cancer? I just got a negative result! (@CathyHannes)

Critical #cancerresearch #Researchpaper in @ASCO @JCO_ASCO on the efficacy of EGFR🛑 in EGFR 🆙 #gastroesophageal #cancer by @DocCatenacci @SteveMaronMD & team. 60 #cancer #patients 43% response rate, PFS 4.6 months. @OncoAlert 🚨#PrecisionMedicine https://t.co/eq4PXzm54E (@BenWestphalen)

@FightCRC @prof_gina_brown @colorectaltweet @colorectal_jay @kgnairmd @DrMikeValente @CoryChevalier @RabiHannaMD @IbrahimSahinMD1 @skopetz @pashtoonkasi @DFarberYoungCRC @prof_gina_brown @CRCequity @colorectal_bio @CYOC_MSK @ccor_study @cacoloncancer @GIcancerDoc @Cologuard (@YLeyfman)

🙏🏾🙏🏾🙏🏾 @katiecouric and @Cologuard , I 💙💙💙the #colorectalcancer screening ad during the Final Four! (@smitha42)

Haven’t seen much discussion on VEGF⛔️ and cholangiocarcinoma. I know I’ve seen patients on and discussions of FOLFIRI+BEV as in this phase-2 study. Having a non-chemo, or non-platinum based systemic option would of value➡️cumulative neuropathy.📈@curecc https://t.co/gdegV0Ca4K (@pashtoonkasi)

#CDH1 - Looking forward to the online NCI #HDGC Symposium next week. Organized by @JeremyLDavisMD and with, amongst others, @SoniaKupfer. I'll be talking about novel Diffuse Gastric Cancer susceptibility genes. https://t.co/0ngHjU0Pdm (@PBenusiglio)

This also came up in our tumor board on the separate question of KRAS+ and lack of benefit Pertuzumab/Trastuzumab in colorectal cancer. I’d imagine that for the antibody drug conjugate, it shouldn’t matter since you are delivering generic chemotherapy. #CRCSM #HER2 💭 (@pashtoonkasi)

https://t.co/NP9chwvse8 The Jacob trial was negative for upfront chemo + Herceptin + perjetta in Gastric cancer The Her2 + in GI malignancies seem to behave differently than breast. Personally ADC would be better if approved (@BijoyTelivala)

.@KReissMD is a #gamechanger #RockStar—- I am always 🌟struck by her! Congrats on this important work in #BRCA➕#PancreaticCancer 💊💊💊@BasserBRCA @letswinpc @PanCAN @lustgartenfdn @SU2C (@drallysonocean)

51 years old, female, uT2N0m0 stomach cancer 1.5cm. MSS, her2 negative, PDL1 CPS-3. Perioperative CT - four cycles of FLOT. Gastrectomy - 0.3 cm residual disease, ypT1b, 41 lymph nodes negatives. What would you recomend ? @YJanjigianMD @duiliorocha_onc @AnelisaCoutinh1 Tks. (@pam65230529)

Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer: Immunity https://t.co/L1ba4OK9bz (@weldeiry)

What if the biomarker is KRAS G12D in #cholangiocarcinoma (@NiteshA75383681)

Trastuzumab + Pertuzumab for Her2/neu positive biliary CCA & GB cancer now in NCCN guidelines (2A) Congrats! @MiteshBorad @DrElkhoueiry @GABOUALFA @VivekSubbiah @melinda_bachini @GIcancerDoc @rachnatshroff @pashtoonkasi @SirohiBhawna @m_khushman @CrainesCrew @genentech (@JavleMilind)

MSH3-Associated Polyposis 🧰1st reported in 2016 in 2 families each w/2 affected siblings 🧰Colorectal & duodenal adenomas, colorectal cancer, gastric cancer, & an early-onset astrocytoma 🧰IHC absence of MSH3 🧰Tumors had eMAST 🧰PMID: 27476653 #ColorectalCancerAwarenessMonth (@HHampel1)

How about that! Rucaparib is now in the @NCCN guidelines for pancreas cancer as a result of @KReissMD phase 2 trial showing potential benefit in pts with BRCA/PALB2 mutations. @mmwatt02 @PennCancer @BasserBRCA https://t.co/pdcUQ4bjei (@TimothyJBrownMD)

👇🏾Power of #SocialMedia #SoMe. From anecdotal reports to @SteveMaronMD chasing down every provider to collectively tell the story. Now published @ASCO @JCO_ASCO. EGFR⛔️in EGFR⬆️⬆️⬆️ #STCSM #ESOCSM. 👀Yes; stomach/esophageal not colorectal.🔐 @OncoAlert https://t.co/9t1ulooTXJ (@pashtoonkasi)

The📉in the incidence of #CUPs #CancerOfUnknownPrimary is mirroring the📈in #cholangiocarcinoma. Testing & finding #IDH1 or #FGFR is not just actionable, but also ✅diagnostic. 💡Confirming site of origin imp. for trials and insurance coverage of drugs. https://t.co/13QCeubbtv (@pashtoonkasi)

In @CD_AACR from @rkalluriMDPhD @MDAndersonNews: Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts (“Tumor-promoting” v “Tumor-restraining”) with Distinct IL-6 Mediated Therapy Resistance in #PancreaticCancer https://t.co/gLQPVCxvHM (@Aiims1742)

The Company successfully introduced HCCscreen in #China as an LDT service for hepatocellular carcinoma, along with establishing channel partnerships involving government procurements, medical examination centers, hospitals, and online platforms. (@GenetronHealth)

New Research article evaluates DCZ0415, an inhibitor of TRIP13, a gene which participates in CRC progression DCZ0415 diminished xenograft tumour growth and inhibited EMT & metastasis 🔓https://t.co/6hWgZXOmbc ✏️@m_khushman @Varambally_S @Umanne @UABNews @ONealCancerUAB #CRCSM (@MolOncology)

#Chugai Obtains Regulatory Approval for #Perjeta and #Herceptin for Additional Indication of #HER2 Positive #ColorectalCancer https://t.co/kb1D1gOz2v (@1stOncology)

Ready ✋—It’s about time. I’ve seen too many #BRCA + patients, who knew they were +, who were never told they were at risk for #PancreaticCancer, who now have advanced #cancer. @letswinpc @BasserBRCA @ASGEendoscopy @quidditch424 @WCM_MeyerCancer @BRCAresponder @LguzzardiM (@drallysonocean)

MUTYH-Associated Polyposis ▪️Biallelic mutations cause ⬆️ risk for adenomas & CRC ▪️Base-excision repair gene ▪️Tumors have mutational signature 36 ▪️~1/100 carrier rate in Caucasians ▪️Carriers may have slight ⬆️ risk for CRC #ColorectalCancerAwarenessMonth (@HHampel1)

Trastuzumab Deruxtecan Shows Efficacy in HER2+ Gastric Cancer. @marshalj23 discusses the DESTINY-Gastric01 study of fam-trastuzumab deruxtecan-nxki in patients with locally advanced or metastatic HER2-positive gastric cancer. @targetedonc @LombardiCancer https://t.co/YI8ltyjUVg (@RueschCenter)

During a debate at the GI Cancers Symposium, Florian Lordick (@FlorianLordick), MD, and Aaron James Scott, MD, argued whether or not knowledge of PD-L1 expression level was needed before starting immune checkpoint inhibitor therapy. #GIcsm #stcsm https://t.co/ovzKEeHPSN (@TargetedOnc)

@YJanjigianMD Reviews #MSI as a #Biomarker in for Localized #GastricCancer #onctwitter #microsatelliteinstability https://t.co/S4nZooO69u via @CancerNetwrk (@intraccsurvivor)

There are at least 5 genes that can cause autosomal recessive adenomatous polyposis (usually 30-100): 👀 MUTYH 👀 MLH3 👀 MSH3 👀 NTHL1 👀 MBD4 #ColorectalCancerAwarenessMonth (@HHampel1)

MTA2 triggered R-loop trans-regulates BDH1-mediated β-hydroxybutyrylation and potentiates propagation of hepatocellular carcinoma stem cells https://t.co/9BACpsl3MO (@ketonemics)

@VanMorrisMD, @MDAndersonNews, discusses approaches in treating BRAF, KRAS Mutated #colorectalcancer @GreatDebatesCME #GDUGI2022 Watch here: https://t.co/l7qgkDQ7nz (@OncLearnNetwork)

🙏@BenWestphalen for🔦this paper This is a tremendous case example to support the National Coop trial led by Vincent Chung at @cityofhope comparing maintenance olaparib +/- pembrolizumab for #PancreaticCancer patients with gBRCA1/2🧬mutations Please consider enrollment‼️ (@MPishvaian)

Pancreatic stellate cells Key drivers of pancreatic fibrosis/inflammation in pancreatitis and stromal dynamics in pancreatic cancers Congrats to Ben and whole team for grinding this one out And don’t forget IL11 inhibits STK11 ⁦@marklewismd⁩ 🔥 https://t.co/dH64LdrFWA (@stuartacook1)

Keep it up 💪! Further update on my loved one w/ a very rare GI tumor & no precision medicine data. Thanks to your GI cases & #bcsm & exciting lung trials (& other cases) for Her2 Tx w/ activating mutations, we got Enhertu started (as figurative funeral bells ringing) Response✨! (@NicoleKuderer)

Keep it up 💪! Further update on my loved one w/ a very rare GI tumor & no precision medicine data. Thanks to your GI tweets & exiting lung & #bcsm trials (& other cases) for Her2 Tx in activating mutations, we got Enhertu started (as literally funeral bells ringing). Response✨! (@NicoleKuderer)

Nivolumab plus chemotherapy improves overall survival in gastric and GEJ adenocarcinoma. Two year survival of 30% especially in PDL1+ tumors. https://t.co/Oqjd46unBu (@DrEzraCohen)

A bittersweet day in clinic... Monica (holding the stomach) is moving on to another role @NCIResearchCtr. We will miss her dearly, and so will our patients! @NCICCR_SurgOnc #CDH1 #GastricCancer (@JeremyLDavisMD)

Germline pathogenic variants in the POLE & POLD1 genes cause Polymerase Proofreading-Associated Polyposis (PPAP). 🔒Autosomal dominant 🔒30-100 adenomas 🔒Possible increased risks for brain & endometrial cancers 🔒Ultrahypermutated tumors #ColorectalCancerAwarenessMonth (@HHampel1)

#hdac #SIRT6 regulates tumor initiation of #coloncancer by controlling glucose metabolism. New study @NatureComms https://t.co/Yp7RuC8Tbu (@AlfredoBudillon)

Very pleased to see our #KRAS #G12C paper in print @JCOPO_ASCO. Many 🙏thanks to @JCO_ASCO editorial team & the reviewers. @ASCO @OncoAlert #precisionmedicine #colorectalcancer #lungcancer ⁦@ASCO_pubs⁩ https://t.co/5YWaXiuz6O (@SalemGIOncDoc)

Very pleased to see our #KRAS #G12C paper in print ⁦⁦@JCOPO_ASCO⁩. Many 🙏thanks to ⁦@JCO_ASCO⁩ editorial team & the reviewers. @ASCO ⁦⁦@OncoAlert⁩ #precisionmedicine #colorectalcancer #lungcancer https://t.co/5YWaXiuz6O (@SalemGIOncDoc)

The ILD/Pneumonitis 🫁 hovers in the 5-15% range with grades varying depending on how vigilant the program/dosing was. Huge advocate of options. But this makes #sequencing an important question with other TKIs & novel agents coming into the #HER2 space. ➡️#CRCSM #ESOCSM #HPBCSM https://t.co/wann7i0yWt (@pashtoonkasi)

Familial Adenomatous Polyposis (FAP): >100 adenomas Usually requires colectomy to prevent CRC Attenuated FAP: 30-100 adenomas Can sometimes be managed w/frequent colonoscopy Caused by mutations in the APC gene 25% of APC mutations are de novo #ColorectalCancerAwarenessMonth (@HHampel1)

Any implications for high copy number MDM2 amplification in addition to ERBB2 (HER2) amplification in #gallbladdercancer? @PTarantinoMD @SKabrajiMD @Aiims1742 @PancPathologist @JavleMilind #HPBCSM #Cholangiocarcinoma #HER2 What else would you use post trastuzumab progression? (@pashtoonkasi)

Picked up an EPCAM🧬mutation to end the day. Important implications for the patient/family. 💡I’ve picked up a lot more germline aberrations by offering testing at diagnosis rather than waiting for the genetics referral. 🪧 #LynchSyndromeAwarenessDay #CRCSM #STCSM #ESOCSM (@pashtoonkasi)

There are at least 4 autosomal dominant genes for adenomatous polyposis: APC, POLE, POLD1, & AXIN2. GREM1 is an autosomal dominant gene that can cause hereditary mixed polyposis. #ColorectalCancerAwarenessMonth (@HHampel1)

Phase II study shows #Ramucirumab, a monoclonal antibody targeting VEGFR-2, was well tolerated but had modest clinical efficacy in patients with advanced or metastatic #BiliaryTractCancer. https://t.co/xXrtiU4q48 @rachnatshroff @JavleMilind (@CCR_AACR)

NTRK, ALK, BRAF and most of all NRG1 rearrangements/fusions in pancreatic cancer. Long list in Cholangiocarcinoma (@fedenichetti)

For BRAF V600e MSS Stage III, there is SU2C arm. For MSI Stage III rectal cancer, a number of important trials in US. (@fireflyann)

I think I would add the word "metastatic"... A lot of stage III KRAS and BRAF colorectal cancer patients getting quite fearful. After chemo, it's worthwhile to know for planning/anticipating next step if recurrence (MSI, HER2, KRAS G12C & BRAF). (@fireflyann)

@KristenCiombor talking about what she knows best, precision medicine (KRAS G12C in this case) in colorectal cancers. Proud to have her @VUMC_Cancer @VUMCHemOnc (@jordanberlin5)

The #PBPS Abstract Award goes to Dr. Burcin Pehlivanoglu! TPPP-BRD9 Fusion-Related Gallbladder Carcinomas are Associated w/Intracholecystic Neoplasia, Neuroendocrine CA and a Distinctive Small Tubular-Type Adenocarcinoma Commonly Accompanied w/Syringomatous Pattern #USCAP2022 (@pbpath)

NOW OPEN: “A Ph2 Study of Preoperative Pembrolizumab for MismatchRepair Deficient, Epstein-Barr Virus Positive and/or PD-L1 Positive Gastric Cancer followed by Chemotherapy & Chemoradiation w/ Pembrolizumab.” #ClinicalTrial @RWJBarnabas @SalmaJabbour1 https://t.co/w18LgMSCGI (@RutgersCancer)

@LiverPath_HPHS #USCAP2022 Up next, Dr Hanlin Wang: FAQs on ancillary tests for hepatobiliary neoplasms. (@liverpath)

Molecular characterization of KRAS wild type pancreas cancers. Represents 10% of PDAC. ⁦@CCR_AACR⁩ ⁦@SWOG⁩ ⁦@krushnacpatra⁩ ⁦@rachnatshroff⁩ ⁦@CathyEngMD⁩ ⁦@FlavioRochaMD⁩ https://t.co/ZbJc67O7M5 (@SyedAAhmad5)

For those 👀looking for NTRK fusions ☝🏽subset to focus on➡️MSI-High #colorectalcancer. My patient who didn’t respond to pembro & IPI/NIVO had a miraculous pCR to TRK⛔️.Still NED! 👇🏾throwback to @TumorBoardTues 2️⃣ As @mcleodhoward mentioned, check if your test has RNA not just🧬 https://t.co/zcjvp7gV2x (@pashtoonkasi)

Very helpful ! What about BRAF mutation in biliary tract cancers ? (@BennounaJaafar)

Nivolumab monotherapy two dose as NAC for gastric cancer showed 5 patients (16%) with MPR(<10% tumor) including 4 MSI-H and 1 MSS patients. Supporting ongoing perioperative trials.#stomachcancer @OncoAlert https://t.co/guJfELCaJx (@KoheiShitara)

Very nice slide. I may just add PALB2 for pancreatic cancer (@m_khushman)

Excited to share our work on KRAS-WT pancreatic cancer in @CCR_AACR https://t.co/ZOO9BCDPvZ A pleasure to work with mentor @paphilip and the team @carisls @weldeiry @marshalj23 @benweinbergmd @DrHendifar @m_khushman @cancerassassin1 @OncoAlert @chadinabhan #Pancsm 🧵 (@ibrahimazaronc)

@KristenCiombor giving a great talk on targeting KRASG12C at @MayoCancerCare #Gicancers (@WuGiOnc)

Just out! @CCR_AACR multi-inst collab @carisls POA #pancsm clinically relevant #KRAS WT subset w/mol targets #PDAC #braf #fgfr2 #alk #ret #ntrk1 #nrg1 #erbb2 #msi #tmb @DrHendifar @paphilip @OncoAlert @m_khushman @marshalj23 @doctormikehall https://t.co/Xrt5oZz1Ak @CSCancerCare (@jgong15)

📢"Drugging the Undruggable" @KristenCiombor from @VanderbiltU is teaching us about KRASG12C as a🎯💊 at the 2022 @MayoCancerCare GI cancer conference 🙏for building our hope with showing us new treatments for our patients 😀 (@MPishvaian)

3) If the liver metastasis has loss of chromosome 13 (del13) as a somatic event, maybe it deleted the germline BRCA2 allele. Testing another tumor (e.g., diagnostic sample) May help. (@CanerSaygin)

'Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma' now online in @CCR_AACR - Dr. Philip et al from @carisls GI Precision Oncology Alliance group. "KRAS-WT PDAC represents 10.7% of PDAC";enriched in IO markers" https://t.co/TsFd0X1FQ4 (@cancerassassin1)

My first presentation en français in more than 3 decades ! La belle langue.. a special thanks to @DucreuxMichel who helped me refine it … 1:30 AM in San Diego —> 9:30 AM à Paris … #jfhod #colorectalcancer #kras @MayoCancerCare (@GIcancerDoc)

Getting pumped for #AACR2022! @AACR Finalizing my #poster for #submission #neworleans #mdphd #phdlife #cancerresearch #PancreaticCancer #cancerstemcell #CXCR1 (@molczyk_caitlin)

Thank you, Michele-one-L! I re-tweeted it because the MSK handle has changed. I hope you, MSK, @EileenMOReilly, and the #Apollo clinical trial are making beautiful science together. 💜 #pancreaticcancer #olaparib #BRCA (@perilonthesea)

Our review highlighting tucatinib in HER-2 mCRC. Ongoing MOUNTANEER trial through @accru__network led by @GIcancerDoc and John Strickler investigating its efficacy in mCRC @MayoCancerCare https://t.co/M2Q69mkDYm (@the_danielahn)

Last, we know that after neoadj CRT, poor TRG benefit from adj nivo in CM577 eso study, mostly only those w high PDL1 (from diagnostic biopsy pre-neoadj tx). This will likely be the same in gastric cancer. Hopefully we will learn more from KN585 et al. https://t.co/IH56sqspSO (@DocCatenacci)

@cgatenbee highlights the importance of spatial context and microenvironment in development of #ColorectalCancer. -how: serial slices & quadrats -surprise: PDL-1 not strong assoc w transition -possible Tx: engineer "hot" vs cold immune ecology @AACR #AACRevol22 (@LambAlastair)

Was impressed be the data from NEONIPIGA study by Thierry André and colleagues. Non-operative treatment of MSI-H gastric cancer seems to be the next challenge to me. Worth studying! (@FlorianLordick)

Phase II study by Lee et al shows that #ramucirumab, a monoclonal antibody targeting VEGFR-2, was well tolerated but had modest clinical efficacy in patients with advanced or metastatic #BiliaryTractCancer. https://t.co/NIqlyjLfK2 @rachnatshroff @JavleMilind (@CCR_AACR)

It starts with knowing your family history. Do you have one of #PancreaticCancer, or known genetic mutations that influence cancer like BRCA. Tagging @drallysonocean and @ShaalanBeg . #PancChat (@letswinpc)

🛰16% of colorectal cancers have microsatellite instability. Of those: 🛰 57% have MLH1 promoter hypermethylation 🛰 26% have Lynch syndrome 🛰 15% have biallelic somatic MMR gene mutations 🛰 2% remain unexplained #ColorectalCancerAwarenessMonth (@HHampel1)

There are about 13 genes that are associated with #PancreaticCancer. Some of them are #BRCA, #ATM, #PALB2, #MLH1 #MSH6, #STK11… who knows the rest? #PancChat (@drallysonocean)

Technological advances in molecular biology in #colorectalcancer with BRAF mutation.🧬 @sediagmolecular @dragon38073853 @Onco_IdISSC @DrMolinaCalzada @VirPalomarColom @GGColoprocto @oncologoRD https://t.co/TUbo849Y2h (@Dr_Ivanoncologo)

There are ~150,000 cases of #colorectal cancer diagnosed each year. A ton of samples are getting extensive genomic profiling. These are expensive tests. Why isn't the info generated used to identify subtypes? Just MSS/MSI-H/BRAF/KRAS isn't enough. #CRCAwarenessMonth (@manjuggm)

PMS2 🏥Pathogenic variants in PMS2 cause #LynchSyndrome 🏥 Lifetime #colorectalcancer risk is 8.7-20% 🏥 Colonoscopy every 1-2 years begins at age 30-35 🏥 Lifetime #EndometrialCancer risk is 13-26% 🏥 Hysterectomy considered after child-bearing #ColorectalCancerAwarenessMonth (@HHampel1)

Patients are our partners in research @NIHClinicalCntr... and sometimes they are like family. Patient deaths can hit particularly hard, even when expected. Today's news was hard. "Without research there is no hope." - PGR #GastricCancer #CDH1 #HDGC .@theNCI #CancerResearch (@JeremyLDavisMD)

MSH6 ⚕️Pathogenic variants in MSH6 cause #LynchSyndrome ⚕️Lifetime #colorectalcancer risk is 10-44% ⚕️Colonoscopy every 1-2 years begins at age 30-35 ⚕️Lifetime #EndometrialCancer risk is 16-49% ⚕️Hysterectomy considered after child-bearing #ColorectalCancerAwarenessMonth (@HHampel1)

Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19–FGFR4–KLB Pathway Inhibition @CD_AACR @AACR https://t.co/QRWiBeJD74 (@VivekSubbiah)

💫Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19–FGFR4–KLB Pathway Inhibition 👉Spotlight @CD_AACR @AACR 👉Delighted to write this commentary with the amazing @montypal @OncoAlert https://t.co/QRWiBeJD74 (@VivekSubbiah)

Thank you for sharing this important change in screening guidelines for pancreatic cancer in patients with BRCA mutation ! (@jamecancerdoc)

⁦@ASGEendoscopy⁩ suggests all BRCA1/2 patients should undergo #pancreaticcancer screening irrespective of their family history Significant change in practice. Who is ready for this? ⁦@HHampel1⁩⁦⁦@CGAIGC⁩ ⁦@DenaTalksDNA⁩⁦@swatigp⁩⁦ (@AparajitaSingh0)

MLH1 🔬Pathogenic variants in MLH1 cause #LynchSyndrome 🔬Lifetime #colorectalcancer risk is 46-61% 🔬Colonoscopy every 1-2 years begins at age 20-25 🔬Lifetime #EndometrialCancer risk is 34-54% 🔬Hysterectomy considered after child-bearing #ColorectalCancerAwarenessMonth (@HHampel1)

@GIcancerDoc promising Ph I/II KRYSTAL-1 results of @Mirati #KRASG12C inh adagrasib monotherapy in refractory KRASG12C MT GI cancers w/ORR 50% in metastatic #PDAC #pancsm and #biliarytract cancer #gicsm. 100% DCR rate across all 30 pts @ASCO #gi22 @sepideh_gholami (@oncologistindia)

MSH2 🧬 Pathogenic variants in MSH2 cause #LynchSyndrome 🧬 Lifetime #colorectalcancer risk is 33-52% 🧬 Colonoscopy every 1-2 years begins at age 20-25 🧬 Lifetime #EndometrialCancer risk is 21-57% 🧬 Hysterectomy considered after child-bearing #ColorectalCancerAwarenessMonth (@HHampel1)

@CathyEngMD sharing her knowledge regarding molecular analysis in colorectal cancer. #SSO2022 KRAS G12C targeted therapy with only 10% response rate. @AlexParikhMD @HoggNDMD @RSnyder_MD @sepideh_gholami @VautheyMD @HopSTranCao @IbrahimSahinMD1 @cancerassassin1 @skopetz (@DenboJw)

Discussing treatment options for #Patients With MSI-H BRAFV600E-Mutated Metastatic #Colorectal #Cancer #ASCODailyNews ⁦@ASCO⁩ Such a great honor to do this with the amazing #CRC scientist Pro Andre! ⁦⁦@OncoAlert⁩ https://t.co/UH3QNGZsHr (@SalemGIOncDoc)

Lynch syndrome is caused by inherited mutations (pathogenic variants) in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2. It can also be caused by large deletions of the 3’ end of EPCAM which lead to inactivation of MSH2. #ColorectalCancerAwarenessMonth (@HHampel1)

European Approval Sought for Ivosidenib in IDH1-Mutated AML and Cholangiocarcinoma @EMA_News #oncology https://t.co/tTPMnhhqhv (@OncLive)

🎯 #ACSCancerchat @JournalCancer 👉 @YJanjigianMD 👉What has been the role of MSI-H/d-MMR in Gastric and GE junction cancers?@CowzerDarren @weoncologists @RamalingamMD @OncoAlert (@VivekSubbiah)

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer https://t.co/GVQo2LIsSk (@VivekSubbiah)

Waterfall plots from the @Nature paper featured as TOP advance in #ACSCancerchat @JournalCancer 👉 The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer @YJanjigianMD @CowzerDarren @weoncologists @RamalingamMD @OncoAlert (@VivekSubbiah)

🎯The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer @nature paper @YJanjigianMD et al https://t.co/GVQo2LIsSk featured in #ACSCancerchat @JournalCancer Top Advances @RamalingamMD @weoncologists (@VivekSubbiah)

@SanoMedCenter large obs cohort CIRCULATE-Japan resected st II-IV #crcsm #Signatera ctDNA post-op 4W ctDNA- approx 97% #DFS rate, in post-op ctDNA+ adj chemo (ACT) cleared #ctDNA w/improved DFS, in post-op 4W ctDNA- no DFS difference b/t ACT vs no ACT #gi22 (@oncologistindia)

@SNUnow PhIII TOPAZ-1 1L durvalumab (PD-L1 inh) + cis/gem vs cis/gem in adv BTC #GIcsm w/#OS benefit 12.8 vs 11.5 mos, irrespective of PD-L1 and subgroups. Note: ABC-02 cis/gem was OS 11.7 ORR 27%, await @SWOG cis/gem/abrax results in this space @ASCO #gi22 (@oncologistindia)

Excellent argument against preop chemo for MSI-H localized gastric cancer by ⁦@LizzySmyth1⁩. “We can cure many MSI H gastric ca w surgery alone.”⁦@IGCCHouston⁩ ⁦@MansfieldPaul⁩ ⁦@ILSONDavid⁩ ⁦@FlorianLordick⁩ (@YJanjigianMD)

New in @CCR_AACR: Comprehensive analysis of R-spondin fusions and RNF43 mutations implicate novel therapeutic options in #colorectalcancer. Dr. Andreas Seeber et al. @carisls GI Precision Oncology Alliance collaboration. https://t.co/a62nHhBIMD #ColorectalCancerAwarenessMonth (@cancerassassin1)

Prolapsing anorectal polyp with pagetoid infiltration of anal squamous epithelium. No submucosal invasion in the polyp and the Pagetoid cells have the same CK7- CK20+ CDX2+ staining as the adenoma #PathTwitter @DrMarkOng @Pathmath1 @ariella8 @RunjanChetty @SingJamieD @kriyer68 (@drtimbracey)

IRAK4 signaling drives resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma - Gastroenterology https://t.co/26ohMf9l6Q (@weldeiry)

New leader Meredith Pelster reviews the highs and lows of IO in GI malignancies. No luck in CRC but neoadj rectal PD1 in st2/3 MMRd is “potentially really exciting “!! ⁦@SarahCannonDocs⁩ (@MLJohnsonMD2)

Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis | Gut #eldeirylab ⁦@carlsen_lindsey⁩ ⁦@tajiknia⁩ ⁦@LanlanZhou⁩ ⁦@shengliang15⁩ https://t.co/uWTDUDgZjQ (@weldeiry)

No patients with disease progression on Adagrasib among KRAS G12C mutated tumors! @MiteshBorad @GIcancerDoc highlights of #gionc @HorizonCME (@Dr_M_Tejani)

Hot off the press ! Diagnosis and Treatment of #Her2 ERBB2-Positive Metastatic #colorectalcancer https://t.co/ciHsOlgjjo via @JAMAOnc part of @JAMANetwork (@GIcancerDoc)

“Sequencing Strategies in the Management of Metastatic Colorectal Cancer With HER2 Amplification” with Kanwal P. S. Raghav, MBBS, MD https://t.co/tOeTYwnmiP @kanwal_raghav @MDAndersonnews #ColorectalCancer (@clinadvances)

We have an international group of experts coming together for this symposium. It will be extraordinary. #HDGC #CDH1 @StoCANcer @StomachCancer_ @NoStomach4Cancr .@theNCI (@JeremyLDavisMD)

#colorectalcancer is preventable with screening and greater awareness of warning signs, especially in the young who are increasingly affected. Learn more here: https://t.co/5nErwwP2ed #ColorectalCancerAwarenessMonth (@SKamath_MD)

@TerriConneran question re KRAS & Co-Mutations PIC3CA HER2 amplifications MET alterations. We have agents for all these Dr. @GIcancerDoc with liquid biopsies we are transforming treatment. We get our first snapshot from tissue biopsy, but he also gets blood draw for a #ctDNA (@fireflyann)

Metformin levels up adiponectin There are several articles showing links between adiponectin and p53 protein. 1/2 Targeting p53/TRAIL/caspase-8 signaling by adiponectin reverses thioacetamide-induced hepatocellular carcinoma in rats - PubMed https://t.co/bU1wXDBAMJ (@Woodynist)

#guardanthealth #guardanthealthamea #guardant360 #liquidbiopsy #colorectalcancer #mCRC (@GuardantAMEA)

Once on a lifetime opportunity, memories to last a lifetime. I love these ladies! #cancer #cancersurvivor #cancerthriver #cancerpatient #crcsm @CologuardGolf @ExactSciences (@ARosen380)

@GIcancerDoc will join @TerriConneran to chat about treatments and recent #KRAS data Tuesday Mar 01, 2:30 PM – 4:00 PM EST Virtual/Live #KickKRAS #events #ColonCancer https://t.co/hXVBb5zuJz (@KRASKickers)

#TTLC22 Dr. Luxi Chen presents P34: a case of a patient with pain and jaundice and a pancreatic head mass with no dominant lung mass. Biopsy showed adenocarcinoma and suspicion was for pancreatic cancer but NGS showed #EGFR mutation and IHC showed TTF1. Diagnosis of NSCLC made. (@StephenVLiu)

Further investigation is coming & needed @drgandara #KickKRAS #TTLC22 @IASLC #KRAS #lungcancer #coloncancer Synergies (@KRASKickers)

Watching some interesting data studies ongoing @drgandara #KickKRAS #TTLC22 @IASLC #KRAS #lungcancer #coloncancer Synergies (@KRASKickers)

Dr. @AMansfieldMD presents mesothelin as a target at #TTLC22. Present in mesothelioma, ovarian cancer, pancreatic cancer, and NSCLC. Multiple strategies being explored. Anetumab ravtansine showed early promise but when randomized to vinorelbine, no improvement in PFS or OS. (@StephenVLiu)

New on @AGA_Gastro: Mucin 5AC-mediated CD44/ITGB1 clustering mobilizes adipose-derived mesenchymal stem cells to modulate #PancreaticCancer stromal heterogeneity https://t.co/Vos9p6NZMD By @KoelinaG @unmc (headed to the Kimmelman Lab @nyulangone for her postdoctoral fellowship). (@Aiims1742)

The frequency of KRAS mutations in pancreatic cancer is about 90%, w/ 2% being KRAS G12C. Adagrasib irreversibly attaches to the protein in its inactive, guanosine diphosphate–bound form and shuts down its activity. @GIcancerDoc @MayoClinic #GI22 https://t.co/ZhzhEUlzAp (@OncLive)

Amazing news for @winterlab8 today. Just found out our paper was accepted to Nature Cancer! Huge congrats to Ali Vaziri-Gohar and @JordanMWinterMD. So proud and lucky to be a part of this amazing research team. #IDH1 #Ivosidenib #pancreaticcancer (@jj_hue)

I have an international list of BRAF experts for Colorectal Cancer... (adapted from all the researchers who were on the international BEACON trial). But would love to add to it e.g. @IbrahimSahinMD1 You can send a DM, if you'd rather be circumspect. https://t.co/kvEGbb3Fo1 (@fireflyann)

From Andrew Biankin: Clinical and molecular characterization of HER2amplified #PancreaticCancer https://t.co/ndRINLw7hy - HER2 amplification occurs in 2% - characterized by a lack of liver metastases, & a preponderance of lung and brain metastases (@Aiims1742)

I’ve treated a few #HER2/ERBB2 driven #cholangiocarcinomas. They don’t respond to chemo.👆🏾tumor is clearly ERBB2 driven (copy number⬆️⬆️⬆️). I’d treat ē a MyPathway like regimen. See our 📝 @Nature_NPJ. > 3 years ongoing response. We also summarized all ERBB2 data in our paper👇🏾. https://t.co/nWn0zI9jPS (@pashtoonkasi)

@curecc @TheLynxGroup Is there anyone in or around #Chicago doing this #HER2 (or other groundbreaking) #cholangiocarcinoma work? (@j12snyder)

Newly Dx Extra-hepatic BTC - HER2 amplification is X298CN @Aiims1742 @pashtoonkasi PD-L1 amplificationX12CN @Dr_R_Kurzrock @EthanSokol @KlempnerSam @oncologician @GIcancerDoc Tx suggestions ? Chemo plus Anti- HER+- Pembro? (@UmutDisel)

Could use help w referrals for international list of KRAS experts for Colorectal Cancer. Have the names of KRAS G12C investigators @GIcancerDoc @mgfakih Want to add pan-KRAS researchers e.g @Benjohnson1112 Will be sharing with @KRASKickers @DrMarkAwad @D_B_McConnell @mvnegrao (@fireflyann)

In the past, as GI oncologists, we didn't think💭much about targeting HER2 outside of gastric/GEJ cancers But, as @BenWestphalen laid out - there is a LOT of very exciting data in #colorectalcancer and #cholangiocarcinoma now as well So be sure to TEST and🤔about HER2🎯Tx‼️ (@MPishvaian)

An important study for patients with early stage colon cancer. Enrolling nationwide and in Canada. #NRG2022 under the great leadership of @VanMorrisMD (@skopetz)

#DocTalk by Dr @AndreaCercek for @colontown She discusses the YO-CRC center at MSKCC--a timely topic as the CRC awareness month approaches For a sneak peek at a sample AMAZING response on her #dostarlimab MSI-H #rectalcancer trial, take a look https://t.co/8bcQ9QXUUZ #CRCSM (@manjuggm)

Well - the timing of this is optimal🙂 ✅Please join us Tuesday, February 22nd (tomorrow) at 8:15PM EST as we discuss HER2 as a target in Breast, Lung, and GI cancers https://t.co/gS8T23BKsJ (@MPishvaian)

@CathyEngMD @Latinamd @GIOncologist @WuGiOnc @HaoXieMDPhD @alshamsi2000 @UaeEma @SocietyEmirates #WorldGI20 @myESMO @NateraOncology #SignateraLooksDeeper @ShankaranVeena @SKamath_MD @NDeVitoMD @MissSheriMD @KimmieNgMD @DrKelseyKlute @rachnatshroff ()

@loconte Sean Ronnekleiv-Kelly @Majeans2011 @GretchenSchwa10 @RoomasaC @AdilHaiderMD @DrHasanAlam @ahyder1 @elliotthaut @ColonCancerDoc @JunaidRazzakMD @AnitaZaidi @murtazaMDPhD @jeremyKratz @MinterWiscSurg @NataliyaUboha (@NabeelZafarMD)

Adagrasib monotherapy demonstrated encouraging clinical activity in patients with previously treated pancreatic ductal adenocarcinoma and other non–colorectal gastrointestinal tumors that harbor KRAS G12C mutations. @GIcancerDoc @MayoClinic @ASCO #GI22 https://t.co/r17E1CxGep (@OncLive)

@CathyEngMD @Latinamd @GIOncologist @WuGiOnc @HaoXieMDPhD @alshamsi2000 @UaeEma @SocietyEmirates #WorldGI20 @myESMO @NateraOncology #SignateraLooksDeeper @ShankaranVeena @SKamath_MD @NDeVitoMD @MissSheriMD @KimmieNgMD @DrKelseyKlute @rachnatshroff ()

@CathyEngMD @Latinamd @GIOncologist @WuGiOnc @HaoXieMDPhD @alshamsi2000 @UaeEma @SocietyEmirates #WorldGI20 @myESMO @NateraOncology #SignateraLooksDeeper @ShankaranVeena @SKamath_MD @NDeVitoMD @MissSheriMD @KimmieNgMD @DrKelseyKlute @rachnatshroff ()

I am thrilled to be a participant in this trial under the care of @EileenMOReilly and to be a part of progress that’s being made with #pancreaticcancer outcomes for #BRCA patients. #hopeful 💜 @KReissMD (@Michele_Miller7)

We are so happy to partner with you. Here’s to a better future for you and others with #PancreaticCancer and #brca or #palb2. 🙏🏻 (@KReissMD)

First in human #clinicaltrial of @Mirati PRMT5 inhibitor MRTX1719 in MTAP deleted cancers (including #PancreaticCancer) https://t.co/dBbO8Dp5mZ (@Aiims1742)

#pancreaticcancer and #gicancers With KRAS G12C Mutation Updated Data on Use of Adagrasib - @ASCOPost @MayoCancerCare @Mirati https://t.co/GqcOp1XpUY (@GIcancerDoc)

Slow is fast, fast is slow! #lungcancer #PancreaticCancer #colorectalcancer.. require different strategies, more complex approaches. That's where all these brilliant minds come in! Early #KRASi are exciting (Adagrasib in particular), but the future is even better! (@CrozrX)

👉🏼The results supported those of FIGHT-202 that led to pemigatinib approval for advanced FGFR2-rearranged cholangiocarcinoma 👉🏼The findings also suggest potential benefit of pemigatinib in multiple other cancers with FGFR rearrangements and/or mutations @OncoAlert (@VivekSubbiah)

#guardanthealthamea #guardanthealth #webinar #guardant360 #biopharma #liquidbiopsy #minimalresidualdisease #MRD #colorectalcancer ()

Prevalence of Germline Sequence Variations Among Patients With #PancreaticCancer in China https://t.co/5ui7KCVPnf Approximately 6% harbor pathogenic variants, with BRCA2 being most common (similar to US). One interesting difference with US population is ⬆️PALB2, ⬇️ATM. (@Aiims1742)

Thanks to #CPRIT for supporting our @MDAndersonNews team to study TGF-beta as a target of micromet CRC. Understanding distinct biology will help bring new therapies & #endcancer for pts w/ ctDNA(+) #crcsm. #TexansConquerCancer (@VanMorrisMD)

Detection of Early-Stage #PancreaticCancer from blood samples: Results of a multiplex biomarker signature validation study https://t.co/miNexRTFUp Multicenter study from @immunovia on their IMMray PanCan-d assay platform. @NCIprevention ()

I honestly didn't know if I would ever see kras become "druggable" in pancreatic adenocarcinoma Early days but a glimmer of hope in updated CodeBreaK100 data on sotorasib in KRAS G12C–mutant PDAC: 21% ORR but 84% DCR -- disease control matters! #pancsm https://t.co/foBpyNoCOp (@marklewismd)

#Fibroblast growth factor receptor (#FGFR) inhibitors in #cholangiocarcinoma: current status, insight on resistance mechanisms and #toxicity management https://t.co/QJNyxi3FO3 @doctorC369 @MayoCancerCare @HeidiDiann (@Amitmahipal79)

➡️ORR ✅FGFR fusions =25.0% ✅FGFR mutations =23.1% ✅partial responses in ➡️cholangiocarcinoma, head and neck, pancreatic, gallbladder, uterine, urothelial carcinoma, recurrent pilocytic astrocytoma, & non-small cell lung cancer @OncoAlert (@VivekSubbiah)

⭐️The results supported those of FIGHT-202 that led to pemigatinib approval for advanced FGFR2-rearranged cholangiocarcinoma @OncoAlert (@VivekSubbiah)

.@GuardantHealth targets #colorectalcancer screening in 2022 - #precisiononcology company aims to launch a #liquidbiopsy #diagnostics test in the first half, rivaling Exact Sciences' Cologuard stool test. https://t.co/Me2rx0FYiM ()

✅Partial responses were achieved in cholangiocarcinoma, head and neck,, pancreatic, gallbladder, uterine, urothelial carcinoma, recurrent pilocytic astrocytoma, & non-small cell lung cancer w FGFR alterations (@VivekSubbiah)

🚨First data for sotorasib in patients w pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy & safety @ASCO #ASCO22 plenaries @OncoAlert ➡️38 patients, 8 pts PR ✅ORR= 21.1% (95% CI: 9.55%-37.32%). ✅DCR= 84.2% @PanCAN https://t.co/r5wKgEOTSI (@VivekSubbiah)

Adagrasib, both alone and in combination with cetuximab, demonstrated encouraging responses and disease control in heavily pretreated patients with KRAS G12C–mutated CRC @DrJaredWeiss @UNC_Lineberger #crcsm https://t.co/0T8kQpSMzn (@OncLive)

Pemigatinib was associated with clinical activity across tumors driven by FGFR fusions+mutations. These results prompted a registrational study in cholangiocarcinoma & phase II/III trials in many tumor types demonstrating the benefit of #PrecisionMedicine in early phase trials. (@VivekSubbiah)